HALOZYME THERAPEUTICS, INC. 8-K

What Happened
Halozyme Therapeutics, Inc. (HALO) announced on March 12, 2026 (filed 8-K) that David Ramsay will become the company’s Interim Chief Financial Officer effective March 23, 2026. Ramsay previously served as Halozyme’s CFO (2003–2009 and 2013–2015) and has recent board and industry experience.

Key Details

• Appointment effective: March 23, 2026. Filing date: March 12, 2026.
• Compensation: $50,000 monthly salary.
• Equity: 10,000 restricted stock units (RSUs) to vest on June 30, 2026 if employed through that date (subject to a one‑year holding period); if still serving on July 1, 2026, an additional 2,500 RSUs will be granted that vest on his termination date (also subject to a one‑year holding period). RSUs granted under the company’s 2021 Stock Plan.
• Background: Age 61; former Halozyme CFO and VP Corporate Development; served as SVP & CFO of Bonti, board member at Savara Inc. and Exuma Biotech; began career at Deloitte & Touche (CPA); B.S. UC Berkeley; M.B.A. Wharton.
• No family relationships or related-party transactions reported.

Why It Matters
An experienced former Halozyme CFO is stepping in on an interim basis, which provides continuity for financial leadership while the company searches for a permanent CFO or manages an immediate transition. The disclosed salary and RSU structure outline the short-term financial cost and incentive alignment tied to his interim service. Investors should note the appointment date and compensation terms; this is an operational / governance update rather than financial results disclosure.